Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05741853 · ClinicalTrials.gov registry record · NA

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

A NA study of Alzheimer Disease and Dementia, sponsored by University of Texas at Austin.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
3
Study locations

NCT05741853: Recruiting NA study of Alzheimer Disease and Dementia, sponsored by University of Texas at Austin.

NCT05741853 is a NA study of Alzheimer Disease and Dementia that is actively recruiting participants, run by University of Texas at Austin. The registered enrollment target is 60 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05741853, a NA study of Alzheimer Disease and Dementia, is actively recruiting participants, sponsored by University of Texas at Austin.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
3
Study locations

Study Summary

Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant need for investigating the effects of treatment that is optimized for bilingual speakers with PPA. This stage 2 efficacy clinical trial seeks to establish the effects of culturally and linguistically tailored speech-language interventions administered to bilingual individuals with PPA. The overall aim of the intervention component of this study is to establish the relationships between the bilingual experience (e.g., how often each language is used, how "strong" each language is) and treatment response of bilinguals with PPA. Specifically, the investigators will evaluate the benefits of tailored speech-language intervention administered in both languages to bilingual individuals with PPA (60 individuals will be recruited). The investigators will conduct an assessment before treatment, after treatment and at two follow-ups (6 and 12-months post-treatment) in both languages. When possible, a structural scan of the brain (magnetic resonance image) will be collected before treatment in order to identify if brain regions implicated in bilingualism are associated with response to treatment. In addition to the intervention described herein, 30 bilingual individuals with PPA will be recruited to complete behavioral cognitive-linguistic testing and will not receive intervention. Results will provide important knowledge about the neural mechanisms of language re-learning and will address how specific characteristics of bilingualism influence cognitive reserve and linguistic resilience in PPA.

Primary Outcome

Percent of intelligible, scripted words for trained scripts and untrained scripts

Conditions Studied

Alzheimer Disease Dementia Primary Progressive Aphasia Neurodegenerative Diseases Dysarthria Language Disorders Frontotemporal Lobar Degeneration Communication Disorders Dementia, Frontotemporal Apraxia, Motor

Interventions

  • BEHAVIORAL Video-Implemented Script Training for Aphasia (VISTA)
  • BEHAVIORAL Lexical Retrieval Training (LRT)

Study Locations (3)

Other

  • Hospital de la Santa Creu i Sant Pau - Barcelona
  • Hospital Clínic de Barcelona - Barcelona

Texas

  • University of Texas at Austin - Austin

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-05-01
Est. Completion 2027-11-30
Phase NA
University of Texas at Austin

257 total trials

What NCT05741853 shows while recruiting

NCT05741853 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower).

The record links to 10 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Video-Implemented Script Training for Aphasia (VISTA) is the first listed.

NCT05741853 reports a single indexed study location in Other, Texas.

Frequently Asked Questions

What is clinical trial NCT05741853 about?

NCT05741853 is a clinical study titled "Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia". Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant need...

What is the current status of trial NCT05741853?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2023-05-01. Estimated completion is 2027-11-30.

What conditions does trial NCT05741853 study?

This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Primary Progressive Aphasia, Neurodegenerative Diseases, Dysarthria.

What interventions are being tested in trial NCT05741853?

The interventions under investigation include: Video-Implemented Script Training for Aphasia (VISTA) (BEHAVIORAL), Lexical Retrieval Training (LRT) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05741853?

This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05741853 being conducted?

This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05741853's enrollment target sits among peer trials

60 187th of 306 higher than 108 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05741853

Source: ClinicalTrials.gov NCT05741853, the US trial registry maintained by the National Library of Medicine. NCT05741853 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.